Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Multiple strain infection of Mycobacterium leprae in a family having 4 patients: A study employing short tandem repeats.

Mohanty PS, Bansal AK, Naaz F, Arora M, Gupta UD, Gupta P, Sharma S, Singh H.

PLoS One. 2019 Apr 4;14(4):e0214051. doi: 10.1371/journal.pone.0214051. eCollection 2019.

2.

Whole Genome Sequencing of Mycobacterium tuberculosis Clinical Isolates From India Reveals Genetic Heterogeneity and Region-Specific Variations That Might Affect Drug Susceptibility.

Advani J, Verma R, Chatterjee O, Pachouri PK, Upadhyay P, Singh R, Yadav J, Naaz F, Ravikumar R, Buggi S, Suar M, Gupta UD, Pandey A, Chauhan DS, Tripathy SP, Gowda H, Prasad TSK.

Front Microbiol. 2019 Feb 26;10:309. doi: 10.3389/fmicb.2019.00309. eCollection 2019.

3.

Potential of adjunctive Mycobacterium w (MIP) immunotherapy in reducing the duration of standard chemotherapy against tuberculosis.

Chahar M, Rawat KD, Reddy PVJ, Gupta UD, Natrajan M, Chauhan DS, Katoch K, Prasad GBKS, Katoch VM.

Indian J Tuberc. 2018 Oct;65(4):335-344. doi: 10.1016/j.ijtb.2018.08.004. Epub 2018 Sep 6.

PMID:
30522622
4.

HPMA-PLGA Based Nanoparticles for Effective In Vitro Delivery of Rifampicin.

Rani S, Gothwal A, Pandey PK, Chauhan DS, Pachouri PK, Gupta UD, Gupta U.

Pharm Res. 2018 Dec 3;36(1):19. doi: 10.1007/s11095-018-2543-x.

PMID:
30511238
5.

Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India.

Moonan PK, Nair SA, Agarwal R, Chadha VK, Dewan PK, Gupta UD, Ho CS, Holtz TH, Kumar AM, Kumar N, Kumar P, Maloney SA, Mase SR, Oeltmann JE, Paramasivan CN, Parmar MM, Rade KK, Ramachandran R, Rao R, Salhorta VS, Sarin R, Sarin S, Sachdeva KS, Selvaraju S, Singla R, Surie D, Tonsing J, Tripathy SP, Khaparde SD.

BMJ Glob Health. 2018 Oct 8;3(5):e001135. doi: 10.1136/bmjgh-2018-001135. eCollection 2018.

6.

Rise of Clinical Microbial Proteogenomics: A Multiomics Approach to Nontuberculous Mycobacterium-The Case of Mycobacterium abscessus UC22.

Advani J, Verma R, Chatterjee O, Devasahayam Arokia Balaya R, Najar MA, Ravishankara N, Suresh S, Pachori PK, Gupta UD, Pinto SM, Chauhan DS, Tripathy SP, Gowda H, Prasad TSK.

OMICS. 2019 Jan;23(1):1-16. doi: 10.1089/omi.2018.0116. Epub 2018 Sep 12.

PMID:
30207826
7.

Smartly Engineered PEGylated Di-Block Nanopolymeric Micelles: Duo Delivery of Isoniazid and Rifampicin Against Mycobacterium tuberculosis.

Rani S, Gothwal A, Khan I, Pachouri PK, Bhaskar N, Gupta UD, Chauhan DS, Gupta U.

AAPS PharmSciTech. 2018 Oct;19(7):3237-3248. doi: 10.1208/s12249-018-1151-8. Epub 2018 Sep 6.

PMID:
30191379
8.

Animal models of tuberculosis: Lesson learnt.

Singh AK, Gupta UD.

Indian J Med Res. 2018 May;147(5):456-463. doi: 10.4103/ijmr.IJMR_554_18. Review.

9.

Autoimmunity to Tropomyosin-Specific Peptides Induced by Mycobacterium leprae in Leprosy Patients: Identification of Mimicking Proteins.

Singh I, Yadav AR, Mohanty KK, Katoch K, Sharma P, Pathak VK, Bisht D, Gupta UD, Sengupta U.

Front Immunol. 2018 Apr 3;9:642. doi: 10.3389/fimmu.2018.00642. eCollection 2018.

10.

Expression profile of CXCL12 chemokine during M. tuberculosis infection with different therapeutic interventions in guinea pig.

Rawat KD, Chahar M, Srivastava N, Gupta UD, Natrajan M, Katoch VM, Katoch K, Chauhan DS.

Indian J Tuberc. 2018 Apr;65(2):152-158. doi: 10.1016/j.ijtb.2017.08.006. Epub 2017 Aug 12.

PMID:
29579430
11.

Protective effect of antigen excess immune complex in guinea pigs infected with Mycobacterium tuberculosis.

Ebenezer RS, Gupta UD, Gupta P, Shakila H.

Indian J Med Res. 2017 Nov;146(5):629-635. doi: 10.4103/ijmr.IJMR_298_16.

12.

Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15.

Cambau E, Saunderson P, Matsuoka M, Cole ST, Kai M, Suffys P, Rosa PS, Williams D, Gupta UD, Lavania M, Cardona-Castro N, Miyamoto Y, Hagge D, Srikantam A, Hongseng W, Indropo A, Vissa V, Johnson RC, Cauchoix B, Pannikar VK, Cooreman EAWD, Pemmaraju VRR, Gillini L; WHO surveillance network of antimicrobial resistance in leprosy.

Clin Microbiol Infect. 2018 Dec;24(12):1305-1310. doi: 10.1016/j.cmi.2018.02.022. Epub 2018 Mar 1.

13.

Ribonucleotide reductase as a drug target against drug resistance Mycobacterium leprae: A molecular docking study.

Mohanty PS, Bansal AK, Naaz F, Gupta UD, Dwivedi VD, Yadava U.

Infect Genet Evol. 2018 Jun;60:58-65. doi: 10.1016/j.meegid.2018.02.013. Epub 2018 Feb 15.

PMID:
29454978
14.

Evaluation of Aggregated Ag85B Antigen for Its Biophysical Properties, Immunogenicity, and Vaccination Potential in a Murine Model of Tuberculosis Infection.

Ahmad F, Zubair S, Gupta P, Gupta UD, Patel R, Owais M.

Front Immunol. 2017 Nov 27;8:1608. doi: 10.3389/fimmu.2017.01608. eCollection 2017.

15.

Reclaiming hijacked phagosomes: Hybrid nano-in-micro encapsulated MIAP peptide ensures host directed therapy by specifically augmenting phagosome-maturation and apoptosis in TB infected macrophage cells.

Sharma A, Vaghasiya K, Gupta P, Gupta UD, Verma RK.

Int J Pharm. 2018 Jan 30;536(1):50-62. doi: 10.1016/j.ijpharm.2017.11.046. Epub 2017 Nov 24.

PMID:
29180254
16.

Assessment of vocation of rifabutin and rifapentine in replace of rifampcin in drug resistance leprosy patients: a molecular simulation study.

Mohanty PS, Naaz F, Bansal AK, Gupta UD.

Mol Biol Res Commun. 2017 Sep;6(3):113-122. doi: 10.22099/mbrc.2017.4084.

17.

Modelling of cerebral tuberculosis in BALB/c mice using clinical strain from patients with CNS tuberculosis infection.

Husain AA, Gupta UD, Gupta P, Nayak AR, Chandak NH, Daginawla HF, Singh L, Kashyap RS.

Indian J Med Res. 2017 Jun;145(6):833-839. doi: 10.4103/ijmr.IJMR_1930_15.

18.

Biological evaluation of novel curcumin-pyrazole-mannich derivative active against drug-resistant Mycobacterium tuberculosis.

Singh AK, Yadav P, Karaulia P, Singh VK, Gupta P, Puttrevu SK, Chauhan S, Bhatta RS, Tadigoppula N, Gupta UD, Chopra S, Dasgupta A.

Future Microbiol. 2017 Nov;12:1349-1362. doi: 10.2217/fmb-2017-0054. Epub 2017 Oct 16.

PMID:
29035081
19.

Sustained expression of DevR/DosR during long-term hypoxic culture of Mycobacterium tuberculosis.

Kumari P, Sikri K, Kaur K, Gupta UD, Tyagi JS.

Tuberculosis (Edinb). 2017 Sep;106:33-37. doi: 10.1016/j.tube.2017.06.003. Epub 2017 Jun 27.

PMID:
28802402
20.

Challenges beyond elimination in leprosy.

Naaz F, Mohanty PS, Bansal AK, Kumar D, Gupta UD.

Int J Mycobacteriol. 2017 Jul-Sep;6(3):222-228. doi: 10.4103/ijmy.ijmy_70_17. Review.

21.

Conjugated and Entrapped HPMA-PLA Nano-Polymeric Micelles Based Dual Delivery of First Line Anti TB Drugs: Improved and Safe Drug Delivery against Sensitive and Resistant Mycobacterium Tuberculosis.

Upadhyay S, Khan I, Gothwal A, Pachouri PK, Bhaskar N, Gupta UD, Chauhan DS, Gupta U.

Pharm Res. 2017 Sep;34(9):1944-1955. doi: 10.1007/s11095-017-2206-3. Epub 2017 Jul 6.

PMID:
28685299
22.

MicroRNA 26a (miR-26a)/KLF4 and CREB-C/EBPβ regulate innate immune signaling, the polarization of macrophages and the trafficking of Mycobacterium tuberculosis to lysosomes during infection.

Sahu SK, Kumar M, Chakraborty S, Banerjee SK, Kumar R, Gupta P, Jana K, Gupta UD, Ghosh Z, Kundu M, Basu J.

PLoS Pathog. 2017 May 30;13(5):e1006410. doi: 10.1371/journal.ppat.1006410. eCollection 2017 May.

23.

Multiple mirror image cervical neurofibromas in neurofibromatosis type 1.

Singh SK, Mankotia DS, Borkar SA, Gupta UD.

Neurol India. 2017 Mar-Apr;65(2):428-429. doi: 10.4103/neuroindia.NI_1370_15. No abstract available.

24.

Importance of the α10 helix for DevR activation: A road map for screening inhibitors against DevR-mediated dormancy of Mycobacterium tuberculosis.

Vashist A, Prithvi Raj D, Gupta UD, Bhat R, Tyagi JS.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S92-S93. doi: 10.1016/j.ijmyco.2016.09.030. Epub 2016 Nov 11.

25.

Murine model of TB meningitis.

Gupta UD, Abbas A, Kashyap RP, Gupta P.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S178. doi: 10.1016/j.ijmyco.2016.10.029. Epub 2016 Nov 19.

26.

Inhalable Particles for "Pincer Therapeutics" Targeting Nitazoxanide as Bactericidal and Host-Directed Agent to Macrophages in a Mouse Model of Tuberculosis.

Gupta A, Meena J, Sharma D, Gupta P, Gupta UD, Kumar S, Sharma S, Panda AK, Misra A.

Mol Pharm. 2016 Sep 6;13(9):3247-55. doi: 10.1021/acs.molpharmaceut.6b00459. Epub 2016 Aug 10.

PMID:
27463245
27.

Chemotherapeutic Evaluation of Guar Gum Coated Chitosan Nanoparticle Against Experimental Tuberculosis.

Goyal AK, Garg T, Rath G, Gupta UD, Gupta P.

J Biomed Nanotechnol. 2016 Mar;12(3):450-63.

PMID:
27280243
28.

Mutation at codon 442 in the rpoB gene of Mycobacterium leprae does not confer resistance to rifampicin.

Lavania M, Hena A, Reja H, Nigam A, Biswas NK, Singh I, Turankar RP, Gupta U, Kumar S, Rewaria L, Patra PK, Sengupta U, Bhattacharya B.

Lepr Rev. 2016 Mar;87(1):93-100.

PMID:
27255062
29.

Preparation and Preclinical Evaluation of Inhalable Particles Containing Rapamycin and Anti-Tuberculosis Agents for Induction of Autophagy.

Gupta A, Sharma D, Meena J, Pandya S, Sachan M, Kumar S, Singh K, Mitra K, Sharma S, Panda AK, Gupta P, Gupta UD, Misra A.

Pharm Res. 2016 Aug;33(8):1899-912. doi: 10.1007/s11095-016-1926-0. Epub 2016 Apr 19.

PMID:
27095353
30.

TLR Agonist Augments Prophylactic Potential of Acid Inducible Antigen Rv3203 against Mycobacterium tuberculosis H37Rv in Experimental Animals.

Mohammad O, Kaur J, Singh G, Faisal SM, Azhar A, Rauf MA, Gupta UD, Gupta P, Pal R, Zubair S.

PLoS One. 2016 Mar 29;11(3):e0152240. doi: 10.1371/journal.pone.0152240. eCollection 2016.

31.

Constitutive expression of SMAR1 confers susceptibility to Mycobacterium tuberculosis infection in a transgenic mouse model.

Yadav B, Malonia SK, Majumdar SS, Gupta P, Wadhwa N, Badhwar A, Gupta UD, Katoch VM, Chattopadhyay S.

Indian J Med Res. 2015 Dec;142(6):732-41. doi: 10.4103/0971-5916.174566.

32.

The α10 helix of DevR, the Mycobacterium tuberculosis dormancy response regulator, regulates its DNA binding and activity.

Vashist A, Prithvi Raj D, Gupta UD, Bhat R, Tyagi JS.

FEBS J. 2016 Apr;283(7):1286-99. doi: 10.1111/febs.13664. Epub 2016 Feb 20.

33.

Lipoprotein LpqS deficient M. tuberculosis mutant is attenuated for virulence in vivo and shows protective efficacy better than BCG in guinea pigs.

Sakthi S, Palaniyandi K, Gupta UD, Gupta P, Narayanan S.

Vaccine. 2016 Feb 3;34(6):735-43. doi: 10.1016/j.vaccine.2015.12.059. Epub 2016 Jan 5.

PMID:
26768127
34.

Characterization of a novel esterase Rv1497 of Mycobacterium tuberculosisH37Rv demonstrating β-lactamase activity.

Singh G, Kumar A, Arya S, Gupta UD, Singh K, Kaur J.

Enzyme Microb Technol. 2016 Jan;82:180-190. doi: 10.1016/j.enzmictec.2015.10.007. Epub 2015 Oct 21.

PMID:
26672466
35.

Improved protection against tuberculosis after boosting the BCG-primed mice with subunit Ag 85a delivered through intact skin with deformable vesicles.

Kumar G, Sharma N, Gupta P, Joshi B, Gupta UD, Cevc G, Chopra A.

Eur J Pharm Sci. 2016 Jan 20;82:11-20. doi: 10.1016/j.ejps.2015.10.023. Epub 2015 Oct 30.

PMID:
26522817
36.

MicroRNA 17-5p regulates autophagy in Mycobacterium tuberculosis-infected macrophages by targeting Mcl-1 and STAT3.

Kumar R, Sahu SK, Kumar M, Jana K, Gupta P, Gupta UD, Kundu M, Basu J.

Cell Microbiol. 2016 May;18(5):679-91. doi: 10.1111/cmi.12540. Epub 2015 Nov 27.

PMID:
26513648
37.

Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model.

Gupta UD, Vemuri N, Gupta P, Kumar V, Tanushree P, Khuller GK.

Indian J Med Res. 2015 Sep;142(3):323-9. doi: 10.4103/0971-5916.166599.

38.

Development and Characterization of Nanoembedded Microparticles for Pulmonary Delivery of Antitubercular Drugs against Experimental Tuberculosis.

Goyal AK, Garg T, Rath G, Gupta UD, Gupta P.

Mol Pharm. 2015 Nov 2;12(11):3839-50. doi: 10.1021/acs.molpharmaceut.5b00016. Epub 2015 Oct 5.

PMID:
26436948
39.

Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis.

Garg T, Rath G, Murthy RR, Gupta UD, Vatsala PG, Goyal AK.

Curr Pharm Des. 2015;21(22):3076-89. Review.

PMID:
26027577
40.

Report of rpoB mutation in clinically suspected cases of drug resistant leprosy: a study from Eastern India.

Hasanoor Reja AH, Biswas N, Biswas S, Lavania M, Chaitanya VS, Banerjee S, Maha Patra PS, Gupta UD, Patra PK, Sengupta U, Bhattacharya B.

Indian J Dermatol Venereol Leprol. 2015 Mar-Apr;81(2):155-61. doi: 10.4103/0378-6323.152185.

41.

MicroRNA let-7 modulates the immune response to Mycobacterium tuberculosis infection via control of A20, an inhibitor of the NF-κB pathway.

Kumar M, Sahu SK, Kumar R, Subuddhi A, Maji RK, Jana K, Gupta P, Raffetseder J, Lerm M, Ghosh Z, van Loo G, Beyaert R, Gupta UD, Kundu M, Basu J.

Cell Host Microbe. 2015 Mar 11;17(3):345-356. doi: 10.1016/j.chom.2015.01.007. Epub 2015 Feb 12.

42.

Molecular mimicry between Mycobacterium leprae proteins (50S ribosomal protein L2 and Lysyl-tRNA synthetase) and myelin basic protein: a possible mechanism of nerve damage in leprosy.

Singh I, Yadav AR, Mohanty KK, Katoch K, Sharma P, Mishra B, Bisht D, Gupta UD, Sengupta U.

Microbes Infect. 2015 Apr;17(4):247-57. doi: 10.1016/j.micinf.2014.12.015. Epub 2015 Jan 8.

PMID:
25576930
43.

Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.

Alam S, Gupta UD, Alam M, Kabir J, Chowdhury ZR, Alam AK.

Indian J Gastroenterol. 2014 Sep;33(5):452-7. doi: 10.1007/s12664-014-0488-5. Epub 2014 Jul 15.

PMID:
25023045
44.

Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs.

Kaur R, Garg T, Malik B, Gupta UD, Gupta P, Rath G, Goyal AK.

Drug Deliv. 2016;23(3):882-7. doi: 10.3109/10717544.2014.920428. Epub 2014 May 28.

PMID:
24870203
45.

Vitamin B12 supplement alleviates N'-nitrosodimethylamine-induced hepatic fibrosis in rats.

Ahmad A, Afroz N, Gupta UD, Ahmad R.

Pharm Biol. 2014 Jan 10. [Epub ahead of print]

PMID:
24405044
46.

Characterization of an acid inducible lipase Rv3203 from Mycobacterium tuberculosis H37Rv.

Singh G, Arya S, Narang D, Jadeja D, Singh G, Gupta UD, Singh K, Kaur J.

Mol Biol Rep. 2014 Jan;41(1):285-96.

PMID:
24234750
47.

Tissue specific heterogeneity in effector immune cell response.

Tufail S, Badrealam KF, Sherwani A, Gupta UD, Owais M.

Front Immunol. 2013 Aug 27;4:254. doi: 10.3389/fimmu.2013.00254. eCollection 2013.

48.

Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis.

Verma RK, Agrawal AK, Singh AK, Mohan M, Gupta A, Gupta P, Gupta UD, Misra A.

Tuberculosis (Edinb). 2013 Jul;93(4):412-7. doi: 10.1016/j.tube.2013.02.012. Epub 2013 Apr 3.

PMID:
23562366
49.

Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice.

Verma RK, Germishuizen WA, Motheo MP, Agrawal AK, Singh AK, Mohan M, Gupta P, Gupta UD, Cholo M, Anderson R, Fourie PB, Misra A.

Antimicrob Agents Chemother. 2013 Feb;57(2):1050-2. doi: 10.1128/AAC.01897-12. Epub 2012 Nov 26.

50.

Molecular mimicry between HSP 65 of Mycobacterium leprae and cytokeratin 10 of the host keratin; role in pathogenesis of leprosy.

Singh I, Yadav AR, Mohanty KK, Katoch K, Bisht D, Sharma P, Sharma B, Gupta UD, Sengupta U.

Cell Immunol. 2012 Jul-Aug;278(1-2):63-75. doi: 10.1016/j.cellimm.2012.06.011. Epub 2012 Jul 20.

PMID:
23121977

Supplemental Content

Loading ...
Support Center